Alimera Sciences to Report Second Quarter 2020 Financial Results on Wednesday, July 29, 2020 and Provide Corporate Update
July 22 2020 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
it will report second quarter 2020 financial results on Wednesday,
July 29, 2020 after the market close.
Management will host a conference call at 9:00 AM ET on
Thursday, July 30, 2020, to review financial results and provide an
update on corporate developments. Following management’s formal
remarks, there will be a question and answer session.
Participants are asked to pre-register for the call
through the following link: http://dpregister.com/10145768. Please
note that registered participants will receive their dial in number
upon registration and will dial directly into the call without
delay. Those without internet access or unable to pre-register may
dial in by calling: 1-866-777-2509 (domestic) or 1-412-317-5413
(international). All callers should dial in approximately 10
minutes prior to the scheduled start time and ask to be joined into
the Alimera Sciences call. The conference call will also be
available through a live webcast, which can be accessed through the
following link:
https://services.choruscall.com/links/alimera200730.html, which is
also available through the company’s website at
https://investors.alimerasciences.com/ALIM/events/3819.
A webcast replay of the call will be available approximately one
hour after the end of the call through August 13, 2020. The replay
can be accessed through the above links or by calling
1-877-344-7529 (domestic) or 1-412-317-0088 (international) and
using access code 10145768. The telephonic replay will be available
until August 13, 2020.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in
the commercialization and development of prescription ophthalmic
pharmaceuticals. Alimera is presently focused on diseases affecting
the back of the eye, or retina, because these diseases are not well
treated with current therapies and affect millions of people in our
aging populations. For more information, please visit
www.alimerasciences.com.
For press inquiries:Jules Abrahamfor Alimera
Sciences917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024